Non-small cell lung cancer is characterized by dramatic changes in phospholipid profiles

Area of Science:

• Oncology
• Biochemistry
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) is a leading global cause of cancer mortality.
• Previous research focused on genomic, transcriptomic, proteomic, and metabolomic changes in NSCLC.
• Phospholipids, crucial for cell function, remain underexplored in NSCLC.

Purpose of the Study:

• To investigate phospholipid alterations in NSCLC using a mass spectrometry-based phospholipidomics approach.
• To identify potential lipid biomarkers for NSCLC diagnosis and subtyping.

Main Methods:

• Lipidomic profiling of 179 phospholipid species in NSCLC and adjacent non-malignant lung tissues from 162 patients (discovery and validation cohorts).
• Utilized shotgun and 2D-imaging mass spectrometry (MS).

Main Results:

• Identified 91 differentially expressed phospholipid species between NSCLC and normal tissues.
• Observed decreased sphingomyelins (SMs) and phosphatidylserines (PSs), and increased phosphatidylinositols (PIs), phosphatidylethanolamines (PEs), and phosphatidylcholines (PCs).
• Lipid markers achieved high accuracy (AUC 0.999) in distinguishing tumor from normal tissue and (AUC 0.885) in differentiating NSCLC subtypes.

Conclusions:

• Uncovered significant, previously unrecognized alterations in phospholipid profiles in NSCLC.
• These findings highlight the potential of phospholipids as biomarkers for NSCLC diagnosis and classification.
• The identified lipid alterations may have important biological implications in lung cancer development.